SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and […]
Tag: PCI
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and…
Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study
WAYNE, Pa., July 19, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in the prospective multicenter RingerTM PTCA study. RingerTM PTCA is one of two clinical studies evaluating […]
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX® Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology versus […]
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
– Researchers used Terumo Health Outcomes’ ePRISM® software to calculate safe contrast volume targets and improve overall patient outcomes – SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ — A new study published in JAMA[1] demonstrated that patients at high risk for acute kidney injury (AKI), the most […]
Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)
WINNIPEG, Dec. 12, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, […]
Non-Culprit Lesions Cause 2x More Subsequent MIs than PCI’d Lesions
by Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) A new study published in the Journal of the American Heart Association shows that AMIs following a percutaneous coronary intervention (PCI) is twice as likely to originate from untreated lesions versus previous stented lesions. Interesting since this […]
How Far Away Are Remote Robotic PCIs?
By Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) Recent studies have featured the benefits of robotic PCI as a feasible way to treat CAD. But at the annual TCT conference Oct. 30, Ryan D. Madder, MD, presented the idea of “tele-stenting” […]
European doctors learn to access the heart from any approach with Baylis devices and expanded training program
TORONTO, Nov. 21, 2017 /PRNewswire/ – Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to […]
Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada
LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) — Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in […]